VJHemOnc is committed to improving our service to you

Share this video  

VJHemOnc is committed to improving our service to you

ERIC 2018 | Opinion on MRD in CLL: routine use or clinical trials?

Measurable residual disease (MRD) is moving into the clinical setting, attracting varying opinions on the method and setting of its use. Here. Kanti Rai, MD, of the Feinstein Institute of Medical Research, Manhasset, NY, discusses his thoughts on the impact and use of MRD in the chronic lymphocytic leukemia (CLL) space. This interview recorded at the European Research Initiative on CLL (ERIC) International Meeting 2018, held in Barcelona, Spain.

Sign-up for our Newsletter!

Keep up to date with all the latest news with our monthly newsletter